Based on these findings, we evaluated the efficacy of ATRA‐PLGA MP at the early stage of arthritis, benchmarking it against CTLA‐4‐Ig and assessing the potential for added therapeutic benefit with combination therapy. This evidence concerns the gene CTLA4 and arthritic joint disease.